Skip to main content
SpringerLink
Log in

Vaccine Development

  • Chapter
  • First Online:
Book cover Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 995 Accesses

Abstract

Intravesical immunotherapy has been proven to be an effective approach for the management of carcinoma in situ and a proportion of high-grade, non-muscle invasive bladder cancers. The use of intravesical Bacillus Calmette-Guerin (BCG) has been extensively studied in this setting, allowing insight into the therapeutic cascade of immune response following BCG exposure. A number of virus-based strategies have been investigated that target ­tumor-specific epitopes in the hope of developing more effective and durable forms of treatment. Herein, we review the mechanistic action of vaccine therapies and report on the rationale and progress of vaccine-based strategies for the treatment of localized bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shah, J.B. and J.M. McKiernan, Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol, 2004. 14(5): 287–293.

    Article  PubMed  Google Scholar 

  2. Pantuck, A.J., et al, Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother, 2004. 27(3): 240–253.

    Article  CAS  PubMed  Google Scholar 

  3. Gomella, L.G., et al, Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol, 2001. 166(4): 1291–1295.

    Article  CAS  PubMed  Google Scholar 

  4. Lam, J.S., et al, Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 2003. 21(5): 354–360.

    CAS  PubMed  Google Scholar 

  5. O'Donnell, M.A., Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer. Expert Rev Anticancer Ther, 2003. 3(6): 809–821.

    Article  PubMed  Google Scholar 

  6. Punnen, S.P., J.L. Chin, and M.A. Jewett, Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol, 2003. 10(2): 1790–1795.

    PubMed  Google Scholar 

  7. Coe, J.E. and J.D. Feldman, Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology, 1966. 10(2): 127–136.

    CAS  PubMed  Google Scholar 

  8. Morales, A., D. Eidinger, and A.W. Bruce, Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 1976. 116(2): 180–183.

    CAS  PubMed  Google Scholar 

  9. Lamm, D.L., et al, Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 1980. 124(1): 38–40.

    CAS  PubMed  Google Scholar 

  10. Alexandroff, A.B., et al, BCG immunotherapy of bladder cancer: 20 years on. Lancet, 1999. 353(9165): 1689–1694.

    Article  CAS  PubMed  Google Scholar 

  11. Prescott, S., et al, Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol, 1992. 147(6): 1636–1642.

    CAS  PubMed  Google Scholar 

  12. Sharma, P., et al, Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res, 2006. 12(18): 5442–5447.

    Article  CAS  PubMed  Google Scholar 

  13. Chatterjee, S.J., et al, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol, 2004. 22(6): 1007–1013.

    Article  CAS  PubMed  Google Scholar 

  14. Fearon, E.R., et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 1990. 60(3): 397–403.

    Article  CAS  PubMed  Google Scholar 

  15. Cote, R.J., et al, Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res, 1998. 58(6): 1090–1094.

    CAS  PubMed  Google Scholar 

  16. Casado, E., et al, Doomed trials for promising adenoviruses: a rationale for success. J Clin Oncol, 2004. 22(6): 1162-3; author reply 1163–1164.

    Article  PubMed  Google Scholar 

  17. Sabichi, A., et al, Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol, 2006. 175(3 Pt 1): 1133–1137.

    Article  CAS  PubMed  Google Scholar 

  18. Loskog, A., et al, Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol, 2001. 166(3): 1093–1097.

    Article  CAS  PubMed  Google Scholar 

  19. Abraham, S., et al, Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res, 2006. 12(2): 353–360.

    Article  CAS  PubMed  Google Scholar 

  20. Zelinski, D.P., et al, EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res, 2001. 61(5): 2301–2306.

    CAS  PubMed  Google Scholar 

  21. Cardillo, M.R., et al, Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res, 2000. 19(2): 225–233.

    CAS  PubMed  Google Scholar 

  22. Nassar, H., et al, Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol, 2004. 17(9): 1045–1050.

    Article  CAS  PubMed  Google Scholar 

  23. Scholl, S.M., et al, Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother, 2000. 23(5): 570–580.

    Article  CAS  PubMed  Google Scholar 

  24. Gilboa, E., et al, Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol, 1994. 5(6): 409–417.

    CAS  PubMed  Google Scholar 

  25. Gansbacher, B., et al, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med, 1990. 172(4): 1217–1224.

    Article  CAS  PubMed  Google Scholar 

  26. Saito, S., et al, Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res, 1994. 54(13): 3516–3520.

    CAS  PubMed  Google Scholar 

  27. Connor, J., et al, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med, 1993. 177(4): 1127–1134.

    Article  CAS  PubMed  Google Scholar 

  28. Jaffee, E.M., et al, High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res, 1993. 53(10 Suppl): 2221–2226.

    CAS  PubMed  Google Scholar 

  29. Larchian, W.A., et al, Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res, 2000. 6(7): 2913–2920.

    CAS  PubMed  Google Scholar 

  30. Siemens, D.R., et al, Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. J Urol, 2003. 170(3): 979–984.

    Article  CAS  PubMed  Google Scholar 

  31. Loskog, A., et al, Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther, 2002. 9(9): 547–553.

    Article  CAS  PubMed  Google Scholar 

  32. Kuball, J., et al, Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol, 2002. 20(4): 957–965.

    Article  CAS  PubMed  Google Scholar 

  33. Pagliaro, L.C., et al, Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol, 2003. 21(12): 2247–2253.

    Article  CAS  PubMed  Google Scholar 

  34. Mastrangelo, M.J., et al,Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther, 1999. 6(5): 409–422.

    Article  CAS  PubMed  Google Scholar 

  35. Okegawa, T., et al, The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res, 2001. 61(17): 6592–6600.

    CAS  PubMed  Google Scholar 

  36. Mastrangelo, M.J. and E.C. Lattime, Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther, 2002. 9(12): 1013–1021.

    Article  CAS  PubMed  Google Scholar 

  37. Mastrangelo, M.J., et al, Poxvirus vectors: orphaned and underappreciated. J Clin Invest, 2000. 105(8): 1031–1034.

    Article  CAS  PubMed  Google Scholar 

  38. Yang, A.S., C.E. Monken, and E.C. Lattime, Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res, 2003.63(20): 6956–6961.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State University of New York, Downstate, Brooklyn, NY, USA

    Nicholas Karanikolas

  2. Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jonathan Coleman

Authors
  1. Nicholas Karanikolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Coleman .

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Karanikolas, N., Coleman, J. (2009). Vaccine Development. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_28

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation